1
|
Silva BM, Macedo FH, Hayano EEM, Germano S, Ribeiro IF, Franco CA, Requião L, Medina-Pestana J, Goes MA. Relationship of hemoglobin levels with outcomes in deceased donor kidney transplant: a retrospective cohort study. J Bras Nefrol 2024; 46:e20230014. [PMID: 38284551 DOI: 10.1590/2175-8239-jbn-2023-0014en] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Accepted: 11/03/2023] [Indexed: 01/30/2024] Open
Abstract
INTRODUCTION Anemia is frequent in patients undergoing replacement therapy for kidney failure. Anemia in the pre- and post-transplantation period might be related to kidney transplant outcomes. The current study therefore sought to assess the relationship between anemia, delayed allograft function (DGF), chronic kidney allograft dysfunction (CAD), and death from any cause following kidney transplantation from a deceased donor. METHODS This was a retrospective study with 206 kidney transplant patients of deceased donors. We analyzed deceased donors' and kidney transplant patients' demographic data. Moreover, we compared biochemical parameters, anemia status, and medicines between DGF and non-DGF groups. Afterward, we performed a multivariate analysis. We also evaluated outcomes, such as CAD within one year and death in ten years. RESULTS We observed a lower frequency of pre-transplant hemoglobin concentration (Hb) but higher frequency of donor-serum creatinine and red blood transfusion within one week after transplantation in the group with DGF. In addition, there was an independent association between Hb concentration before transplantation and DGF [OR 0.252, 95%CI: 0.159-0.401; p < 0.001]. There was also an association between Hb concentration after six months of kidney transplantation and both CAD [OR 0.798, 95% CI: 0.687-0.926; p = 0.003] and death from any cause. CONCLUSION An association was found between pre-transplantation anemia and DGF and between anemia six months after transplantation and both CAD and death by any cause. Thus, anemia before or after transplantation affects the outcomes for patients who have undergone kidney transplantation from a deceased donor.
Collapse
Affiliation(s)
| | | | | | - Suzeli Germano
- Universidade Federal de São Paulo, Divisão de Nefrologia, São Paulo, SP, Brazil
| | | | - Carolina Azze Franco
- Universidade Federal de São Paulo, Departamento de Medicina, São Paulo, SP, Brazil
| | - Lucio Requião
- Universidade Federal de São Paulo, Divisão de Nefrologia, São Paulo, SP, Brazil
- Universidade Federal de São Paulo, Hospital do Rim, São Paulo, SP, Brazil
| | - José Medina-Pestana
- Universidade Federal de São Paulo, Divisão de Nefrologia, São Paulo, SP, Brazil
- Universidade Federal de São Paulo, Hospital do Rim, São Paulo, SP, Brazil
| | - Miguel Angelo Goes
- Universidade Federal de São Paulo, Divisão de Nefrologia, São Paulo, SP, Brazil
- Universidade Federal de São Paulo, Hospital do Rim, São Paulo, SP, Brazil
| |
Collapse
|
2
|
Restrepo-Aristizábal C, Giraldo LM, Franco CA, Tobón JV, Ascencio JL, Torres-Bustamante M, Zuluaga MI. Neuromyelitis optica spectrum disorders relapses and seasonal influence in an equatorial country cohort. Rev Neurol 2024; 78:127-133. [PMID: 38416504 DOI: 10.33588/rn.7805.2023286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/29/2024]
Abstract
INTRODUCTION Information about seasonal distribution of Neuromyelitis optica spectrum disorders (NMOSD) attacks, particularly in tropical countries, has rarely been described and the reported data are diverse. OBJECTIVE To evaluate influence of seasonal variation in NMOSD relapses in an equatorial country. PATIENTS AND METHODS Exploratory observational, retrospective ecological study in a cohort of patients with NMOSD followed from January 2008 to December 2019. Data of demographic, clinical information, characteristics of relapses and seasonal temporal variation were recorded. Also, the annual, monthly and intra-annual seasonal variation of relapses was quantified. A negative binomial regression was used to estimate the associations between the number of relapses and climatic and temporal variables. RESULTS One hundred thirteen patients were included, most of them were female (89.38%), with a mean age at NMOSD diagnosis was 44.97 (±13.98) and the median of relapses per patient were 2 relapses (IQR 1-3). The patients presented 237 relapses, most of these in AQP4 seropositive patients (87.76%) and longitudinal extensive myelitis was the most frequent type of relapse (53.59%). According to the temporal variation, relapses were more common in the second rainy season (28.69%) during November and December. However, there weren't significant differences in the number of relapses between seasons and climatic variables in the multivariable model. CONCLUSION The number of NMOSD relapses in this equatorial country cohort did not exhibit any significant associations with climatic variations, including changes in rainy or dry seasons.
Collapse
Affiliation(s)
- C Restrepo-Aristizábal
- Universidad CES, Medellín, Colombia
- Fundación Instituto Neurológico de Colombia, Medellín, Colombia
| | - L M Giraldo
- Fundación Instituto Neurológico de Colombia, Medellín, Colombia
| | - C A Franco
- Universidad CES, Medellín, Colombia
- Fundación Instituto Neurológico de Colombia, Medellín, Colombia
| | - J V Tobón
- Universidad CES, Medellín, Colombia
- Fundación Instituto Neurológico de Colombia, Medellín, Colombia
| | - J L Ascencio
- Fundación Instituto Neurológico de Colombia, Medellín, Colombia
| | | | - M I Zuluaga
- Universidad CES, Medellín, Colombia
- Fundación Instituto Neurológico de Colombia, Medellín, Colombia
| |
Collapse
|
3
|
Restrepo-Aristizábal C, Giraldo LM, Giraldo YM, Pino-Pérez AM, Álvarez-Gómez F, Franco CA, Tobón JV, Ascencio JL, Zuluaga MI. PLEX: the best first-line treatment in nmosd attacks experience at a single center in Colombia. Heliyon 2021; 7:e06811. [PMID: 33948520 PMCID: PMC8080073 DOI: 10.1016/j.heliyon.2021.e06811] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Revised: 03/08/2021] [Accepted: 04/12/2021] [Indexed: 02/09/2023] Open
Abstract
Objective Primary outcome was to evaluate complete improvement at six months after acute treatment in NMOSD relapses. Methods Retrospective observational cohort study of patients with diagnosis of NMOSD admitted for acute attacks. We performed an explanatory analysis using the univariate, bivariate and multivariate logistic regression approach. We compared survival curves using the Kaplan Meier analysis and estimated the median time for the main outcome. Results In the univariate analysis, basal EDSS score, AQP4-IgG positivity, PLEX as a first-line treatment (IVMP + PLEX), less systemic complications related to acute treatment and total attack history were independently associated with complete improvement at six months. After adjusting for confounding variables and using multivariate analysis by Cox Regression, positive AQ4-IgG (HR 0.04, 95% CI: 0.02–0.66) and IVMP + PLEX (HR 5.1, 95% CI: 3.9–66.4), were kept as independent factors associated to time to complete improvement. Time from admission to PLEX initiation and complete improvement at six months had a median of seven days (95% CI: 5.2–8.8). In secondary effects, there were no statistical differences between the groups. Conclusions PLEX + IVMP is the treatment of choice for NMOSD relapses and should be initiated as early as possible.
Collapse
Affiliation(s)
- C Restrepo-Aristizábal
- Neurology, Instituto Neurológico de Colombia (INDEC) Medellín, Colombia.,Neurology, CES University Medellín, Colombia
| | - L M Giraldo
- Neurology, Instituto Neurológico de Colombia (INDEC) Medellín, Colombia.,Neurology, CES University Medellín, Colombia
| | - Y M Giraldo
- Epidemiology, Biostatistics CES University; Medellín, Colombia
| | - A M Pino-Pérez
- Neurology, Instituto Neurológico de Colombia (INDEC) Medellín, Colombia.,Neurology, CES University Medellín, Colombia
| | - F Álvarez-Gómez
- Neurology, Instituto Neurológico de Colombia (INDEC) Medellín, Colombia.,Neurology, CES University Medellín, Colombia
| | - C A Franco
- Neurology, Instituto Neurológico de Colombia (INDEC) Medellín, Colombia.,Neurology, CES University Medellín, Colombia
| | - J V Tobón
- Neurology, Instituto Neurológico de Colombia (INDEC) Medellín, Colombia.,Neurology, CES University Medellín, Colombia
| | - J L Ascencio
- Neurorradiology, Instituto Neurológico de Colombia, Medellín, Colombia
| | - M I Zuluaga
- Neurology, Instituto Neurológico de Colombia (INDEC) Medellín, Colombia.,Neurology, CES University Medellín, Colombia
| |
Collapse
|
4
|
Bichuetti DB, Franco CA, Elias I, Mendonça ACR, Carvalho LFD, Diniz DS, Tur C, Tintoré M, Oliveira EMLD. Multiple sclerosis risk perception and acceptance for Brazilian patients. Arq Neuropsiquiatr 2018; 76:6-12. [PMID: 29364388 DOI: 10.1590/0004-282x20170167] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/19/2017] [Accepted: 09/14/2017] [Indexed: 01/22/2023]
Abstract
The perception of multiple sclerosis (MS) severity and risk associated with therapies might influence shared decision making in different countries. We investigated the perception of MS severity and factors associated with risk acceptance in Brazil in 96 patients with relapsing-remitting MS using a standardized questionnaire and compared this with two European cohorts. Multiple sclerosis was perceived as a very severe disease and the risk of developing progressive multifocal leukoencephalopathy due to natalizumab was seen as moderate to high. Seventy-six percent considered a risk of 1:1,000, or higher, an impediment for natalizumab use. Older age was the only variable associated with higher risk acceptance and our patients showed a more conservative profile than German and Spanish patients. Our patients perceived MS severity and progressive multifocal leukoencephalopathy risk similarly to elsewhere, but their willingness to take risks was more conservative. This should be considered when discussing therapeutic options and it might have an impact on guideline adaptations.
Collapse
Affiliation(s)
| | - Carolina Azze Franco
- Universidade Federal de São Paulo, Disciplina de Neurologia, São Paulo SP, Brasil
| | - Isaac Elias
- Universidade Federal de São Paulo, Disciplina de Neurologia, São Paulo SP, Brasil
| | - Andreia C R Mendonça
- Universidade Federal de Goiás, Faculdade Estácio de Sá de Goiás,Centro de Referência e Investigação em Esclerose Múltipla, Goiânia GO, Brasil
| | - Lorraine Fiama Diniz Carvalho
- Universidade Federal de Goiás, Faculdade Estácio de Sá de Goiás,Centro de Referência e Investigação em Esclerose Múltipla, Goiânia GO, Brasil
| | - Denise Sisterolli Diniz
- Universidade Federal de Goiás,Centro de Referência e Investigação em Esclerose Múltipla, Goiânia GO, Brasil
| | - Carmen Tur
- Universitat Autònoma de Barcelona, Hospital Universitari Valld'Hebron, Centre of Catalonia, Department of Neurology-Neuroimmunology and Multiple Sclerosis, Barcelona Spain.,University College London, Institute of Neurology, Department of Neuroinflammation, London, United Kingdom
| | - Mar Tintoré
- Universitat Autònoma de Barcelona, Hospital Universitari Valld'Hebron, Centre of Catalonia, Department of Neurology-Neuroimmunology and Multiple Sclerosis, Barcelona Spain
| | | |
Collapse
|
5
|
Michelin MA, Merino LM, Franco CA, Murta EFC. Pregnancy outcome after treatment of cervical intraepithelial neoplasia by the loop electrosurgical excision procedure and cold knife conization. CLIN EXP OBSTET GYN 2009; 36:17-19. [PMID: 19400411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
PURPOSE OF INVESTIGATION The aim of this study was to evaluate the effect of LEEP and cold-knife conization on the outcome of subsequent pregnancy in a tertiary public hospital. METHODS One hundred and ninety-nine patients met the inclusion criteria (age between 18 and 45 years old). Cold-knife conization, LEEP, and both (conization and LEEP) were performed in 102 (51.3%), 95 (47.7%) and two (1%) women, respectively. Average ages were respectively, 33 +/- 7.3; 25 +/- 6.73 and 30 +/- 2.8. RESULTS Pregnancies occurred 2.6 and 4.8 years after LEEP and conization, respectively. Miscarriages and preterm pregnancies were more frequent in conization cases versus LEEP, 26% and 5.2%, 23% and 5.5%, respectively. CONCLUSION If patients express a desire for pregnancy, LEEP should be the procedure of choice.
Collapse
Affiliation(s)
- M A Michelin
- Research Institute of Oncology (IPON), Discipline of Gynecology and Obstetrics, Federal University of Triangulo Mineiro, Uberaba, MG, Brazil
| | | | | | | |
Collapse
|
6
|
Abstract
A new antiviral nucleoside, BMS-180194 [1R-(1 alpha, 2 beta, 3 alpha)]- 2-amino-9[2,3-bis(hydroxymethyl)cyclobutyl]-1,9dihydro-6H-purin-6- one, is a broad spectrum antiviral agent. The antiviral effectiveness of BMS-180194 against murine cytomegalovirus (MCMV) infection in immunocompromised C57BL/6 mice was investigated and was compared to that of ganciclovir (GCV). LP-BM5 murine retrovirus complex-induced immunocompromised C57BL/6 mice were challenged with MCMV then treated intraperitoneally or per os with various doses of BMS-180194 ranging from 30 to 3 mg/kg/day. When administered intraperitoneally, BMS-180194 was effective against MCMV-mediated mortality in a dose-dependent manner demonstrating a 50% protective dose (PD50) of 3.12 mg/kg/day which was comparable to that of GCV. There was a marked reduction in organ MCMV titers in BMS-180194-treated animals (10-10,000- fold lower than the placebo controls). Similar findings were observed when the compound was administered orally. Interestingly, oral BMS-180194 demonstrated a similar antiviral efficacy as that obtained by the parental route of administration suggesting a high oral bioavailability of the compound. Oral ganciclovir treatment, however, required more than a 4-fold higher amount of GCV to confer the same degree of protection obtained by a parenteral route of administration. Oral BMS-180194 was also effective in reducing the organ MCMV titer in genetically severe combined immunodeficient (SCID) mice. The parenteral or oral antiviral efficacy of BMS-180194 was comparable to that of parenteral ganciclovir against MCMV infection in the present study. Doses of BMS-180194 employed in the present study showed no toxicity to mice. These results suggest that BMS-180194 may be of value as an oral antiviral agent for treatment of opportunistic CMV infections in immunocompromised individuals.
Collapse
Affiliation(s)
- H Yang
- Department of Microbiology, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492-7600, USA
| | | | | | | |
Collapse
|